Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

The "Keytruda Market Size, Share & Trends Analysis Report By Application (Lung Cancer, Breast Cancer, Melanoma, Hodgkin Lymphoma), By Payer (Commercial/Private, Public), By Distribution Channel, By ...

Mural Oncology is halting development of its lead IL-2 therapy and enacting major layoffs after its second trial failure this ...

Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in chemotherapy.

Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients' lives could be significantly ...

Oncology is the company's most important field. It markets Keytruda, a cancer drug that topped the list of the world's best-selling drugs last year. Keytruda will run out of patent exclusivity in the ...

Most people receive Keytruda infusions for up to 2 years. But in some cases, treatment may last longer if there’s evidence that the drug is still effective and the side effects are minimal.

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly ...

A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

MSD’s subcutaneous (SC) Keytruda (pembrolizumab) has shown non-inferior pharmacokinetics (PK) to the intravenous (IV) version of the company’s blockbuster therapy in a pivotal trial.